Sheetz launches new vodka sodas just in time for summer
ALTOONA, Pa. (WTAJ) — Just in time for summer, Sheetz is heating things up and cooling you down with the launch of two new peach-flavored vodka sodas hitting shelves Tuesday, June 3, at all Pennsylvania locations.
Shpiked® Peach Ringz and its stronger sibling, Shpiiiked® Peach Ringz, are the latest adult beverages developed in collaboration with Slushed Brands, LLC. Both drinks are infused with peach gummy rings and premium distilled vodka for a bold, summery flavor.
The lighter Shpiked® version carries a 5% alcohol by volume (ABV), while Shpiiiked® packs a punch at 8% ABV. Single 16-ounce cans retail at $2.19, and six-pack 12-ounce cans go for $11.99.
Pirates fans in Pittsburgh won't have to wait to get a taste. Shpiiiked® Peach Ringz is already available inside PNC Park and will remain on sale throughout the rest of the 2025 baseball season.
The drinks are marketed as ideal companions for beach trips, poolside lounging and ballpark outings.
Sheetz emphasized its continued commitment to responsible alcohol sales. Employees will request valid ID for all alcohol purchases, and each store will adhere to Pennsylvania's time-of-day sales laws.
For store locations and more information, visit www.sheetz.com.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Cepheid Receives Health Canada Licence for Xpert® HIV-1 Viral Load XC
Next-Generation Molecular Test for Monitoring Viral Load and HIV-1 Infection SUNNYVALE, Calif., June 4, 2025 /CNW/ -- Cepheid today announced that Health Canada has issued Cepheid a medical device licence for Xpert® HIV-1 Viral Load XC, a next-generation extended-coverage (XC) test intended to aid in assessing HIV viral load levels, which are used to monitor effectiveness of antiretroviral treatment. Xpert® HIV-1 Viral Load XC dual target test provides extended strain coverage ensuring a high level of performance with a simple workflow to improve patient access to the standard of care and help achieve UNAIDS HIV targets by 2030.1 "Xpert® HIV-1 Viral Load XC leverages dual target technology to improve detection while maintaining the flexibility to be performed on-demand in as little as 90 minutes." said Vitor Rocha, President of Cepheid. "Access to the test can enhance patient care, as measurement of HIV viral load informs treatment plans while fast results enable earlier interventions with counseling and therapy." The test is designed for use on any of Cepheid's GeneXpert® Systems which provide simple, reference lab quality PCR testing on location in laboratory environments at medical centers and hospitals or in community health clinics and physician offices. Xpert® HIV-1 Viral Load XC will begin shipping to customers in Canada in June 2025. Visit for more information. Malisa et al 2023 Nature Scientifc Reports | (2023) 13:4578https:// About CepheidBased in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is an operating company within Danaher Corporation's Diagnostics platform. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit IVD. In Vitro Diagnostic Medical Device. May not be available in all countries For Cepheid Media Inquiries:Darwa SOURCE Cepheid View original content to download multimedia: Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
32 minutes ago
- Yahoo
Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)
BEIJING & NANJING, China, June 04, 2025--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. ("NJCTTQ") announced that NTB003 (formerly BCG009), a co-developed injectable drug candidate, has received the Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA). The approved indication is Thyroid Eye Disease (TED). About NTB003 Injection NTB003 is a second-generation fully human anti-IGF-1R monoclonal antibody co-developed by Biocytogen and Nanjing Chia Tai Tianqing. Antibody discovery and optimization were completed by Biocytogen using its proprietary RenMab™ fully human antibody discovery platform, while Nanjing Chia Tai Tianqing was responsible for CMC process development, GLP-compliant toxicology studies, and IND application. Compared with first-generation approved anti-IGF-1R therapeutics, NTB003 demonstrates enhanced molecular affinity, improved druggability, and an extended half-life. In vitro studies have shown that NTB003 exerts potent signal-blocking activity and effectively inhibits the release of hyaluronic acid (HA), indicating strong potential for further clinical development. Clinical studies of teprotumumab and other investigational anti-IGF-1R biologics have demonstrated that targeting IGF-1R can deliver significant clinical benefits. These agents have shown rapid onset of therapeutic response and favorable outcomes in reducing proptosis and diplopia, improving quality of life, and lowering clinical activity scores in patients with TED. Nanjing Chia Tai Tianqing will lead the clinical development and commercialization of NTB003 in China, aiming to provide an improved therapeutic option for Chinese TED patients. Biocytogen will be responsible for the global out-licensing of the product outside China. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit View source version on Contacts Biocytogen Contacts Antibody assets and platforms: BD-Licensing@ Media: pr@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
42 minutes ago
- Associated Press
Nasdaq Launches Exclusive Access to Nasdaq Private Market's Tape D® API to Deliver Advanced Visibility into Private Markets
NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Nasdaq® (Nasdaq: NDAQ) announced today that the company has partnered with Nasdaq Private Market (NPM), a leading provider of secondary liquidity solutions to private companies, employees, and investors, to provide greater price transparency and valuation visibility into private, pre-IPO companies, including unicorns and other startups through NPM's Tape D® private company dataset. As the exclusive distributor of the Tape D API, Nasdaq is enhancing essential transparency and access to an increasingly complex private company landscape. Now available to Nasdaq clients through API integration via Nasdaq Data Link, Tape D addresses critical transparency challenges by helping investors evaluate private holdings with greater confidence, enabling banks to structure private transactions more effectively, supporting wealth advisors and shareholders in managing liquidity needs, and equipping private companies with valuable insights for capital raises and tender offers. This comprehensive data product delivers real-time private market pricing by seamlessly integrating primary round data, secondary market transactions, and accounting data including mutual fund marks and 409A valuations. 'Nasdaq was founded on the principle of leveraging technology to make markets more efficient, and we are committed to driving the same transformation in private markets that we've achieved in public markets,' said Oliver Albers, Executive Vice President, Chief Product Officer, Capital Access Platforms at Nasdaq. 'The collaboration with Nasdaq Private Market builds upon this foundation, reflecting Nasdaq's continued commitment to creating an ecosystem where transparency, accessibility, and improved outcomes naturally extend across the entire investment lifecycle,' noted Albers. 'The private market is now a critical arena for valuation, investment, and planning, and requires accurate, real-time data. With over 1,200 unicorns and billions in equity held by private shareholders, the need for a reliable valuation benchmark is greater than ever. Tape D brings essential clarity to private markets, and we are excited to partner with Nasdaq to broaden access to market participants,' said Marc Perkins, CFA, Senior Vice President of Product at Nasdaq Private Market. In addition to the Tape D API from Nasdaq, NPM offers individual subscriptions directly via NPM's website. The launch of this data partnership with Nasdaq Private Market marks the latest step in Nasdaq's commitment to enhancing transparency, access, and portfolio management capabilities across the public-to-private investment spectrum. This includes offerings such as Nasdaq Fund Secondaries, which bring greater efficiency, transparency, and scalability to secondary transactions. Nasdaq also delivers solutions designed to equip asset owners and asset allocators with essential research and portfolio management tools that span both public and private markets. These enhancements address specific market challenges, helping managers clearly articulate their value propositions to gather assets while giving allocators the visibility they need for confident decision making. For more information about accessing the Nasdaq Private Market Tape D Data API, please visit: About Nasdaq Nasdaq (Nasdaq: NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at Nasdaq® is a registered trademarks of Nasdaq, Inc. The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither Nasdaq, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies or Nasdaq proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED. © 2025. Nasdaq, Inc. All Rights Reserved. About Nasdaq Private Market Nasdaq Private Market provides liquidity, wealth and data solutions for private companies, employees, and investors throughout each stage of the pre-IPO lifecycle. Since inception over a decade ago, NPM has executed nearly $60 billion in transactional volume for 200,000+ individual eligible employee shareholders and investors across 775+ company-sponsored liquidity programs. Founded within Nasdaq, Inc. in 2013, today NPM is an independent company with strategic investments from Nasdaq, Allen & Company, Bank of America, BNP Paribas, Citi, DRW Venture Capital, Goldman Sachs, HiJoJo Partners, Morgan Stanley, UBS, and Wells Fargo. Learn more at Visit LinkedIn and X for the latest company news. Disclosures and Disclaimers NPM is not: (a) a registered exchange under the Securities Exchange Act of 1934; (b) a registered investment adviser under the Investment Advisers Act of 1940; or (c) a financial or tax planner and does not offer legal or financial advice to any user of the NPM website or its services. Securities-related services are offered through NPM Securities, LLC, a registered broker-dealer and alternative trading system, and member FINRA/SIPC. Transactions in securities conducted through NPM Securities, LLC are not listed or traded on The Nasdaq Stock Market LLC, nor are the securities subject to the same listing or qualification standards applicable to securities listed or traded on The Nasdaq Stock Market LLC. Please read these other important disclosures and disclaimers about NPM found here: Contact: Max Leitenberger Corporate Communications, Nasdaq [email protected] Amanda Gold Chief of Staff and Chief People Officer, Nasdaq Private Market [email protected]
